Drawing for PURICYTE

USPTO serial 97127283

PURICYTE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MANGUBAT,ALEXANDER GEORGE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PURICYTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Holly L. Collins

Holly L. Collins NELSON MULLINS RILEY & SCARBOROUGH LLP301 SOUTH COLLEGE STREETSUITE 2300, IP DEPARTMENTCHARLOTTE, NC 28202

Goods and services

ClassDescriptionStatusFirst use
005Therapeutic and regenerative products, namely, blood components in the nature of stem cells and bone marrow concentrate for medical useACTIVE—
010Medical device made of plastic materials used to assist in the separation and isolation of platelet rich plasma blood component from whole blood and indicated for regenerative medical applicationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 5, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 5, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 5, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 5, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 31, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 31, 2025EX5GSOU EXTENSION 5 GRANTED—
Jul 31, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 15, 2025EXT5SOU EXTENSION 5 FILED—
Apr 15, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 16, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 16, 2024EX4GSOU EXTENSION 4 GRANTED—
Sep 16, 2024EXT4SOU EXTENSION 4 FILED—
Sep 16, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 13, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 12, 2024EX3GSOU EXTENSION 3 GRANTED—
Apr 12, 2024EXT3SOU EXTENSION 3 FILED—
Apr 12, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 14, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 12, 2023EX2GSOU EXTENSION 2 GRANTED—
Oct 12, 2023EXT2SOU EXTENSION 2 FILED—
Oct 12, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 25, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 21, 2023EX1GSOU EXTENSION 1 GRANTED—
Apr 21, 2023EXT1SOU EXTENSION 1 FILED—
Apr 21, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 29, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 4, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 4, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 14, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 31, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 26, 2022DOCKASSIGNED TO EXAMINER—
Nov 22, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 19, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance